Nordic Life Science conference: Nordic Life Science collaboration for stronger competitiveness
The Nordic national associations of the pharmaceutical industry invite interested parties to a digital conference on 18 March to discuss how national Life Science Strategies and increased collaboration can lead to a more competitive Nordic region.
Together the Nordic countries can offer world-class research and research infrastructures, healthcare systems of high international standard, competitive Life Science companies and world-leading innovation. To deal with the ever increasing global Life Science competition, the Nordic countries are all implementing national initiatives and strategies to improve the conditions for Life Science and medical research, development and innovation. As more and more countries are increasing their activities and investments in Life Science, both inside and outside Europe, what is required to make the Nordic region an internationally leading Life Science region?
The conference will highlight ongoing Life Science initiatives in the Nordics and discuss if national strategies and increased collaboration between the Nordic countries can be the way forward to improve the competitiveness of the Nordic region as a whole?
Date: Thursday 18 March 2021
Time: 13:00–15:30 CET.
Place: Digital
Registration:
Please register here, at the latest on 17 March 2021, 15.00.
Krister Nilsson, State Secretary to the Minister for Foreign Trade and Nordic Affairs, Jenni Nordborg, Head of Swedish Life Science Office, Carsten Kjaer Joensen, Head of Danish Life Science Office, Gloria Traina, Advisor, Departement of Specialist Health Care, Norway.
Programme
13:00 Welcome
Anders Blanck, CEO, Lif – the research-based pharmaceutical industry (Sweden)
13:05 Introductory speech
Krister Nilsson, State Secretary to the Minister for Foreign Trade and Nordic Affairs
13:15 How can national Life Science Strategies and a White paper on Health Industry lead to a more competitive Nordic region?
What can we learn from the implementation of the different strategies so far?
Jenni Nordborg, Head of Swedish Life Science Office
Carsten Kjaer Joensen, Head of Danish Life Science Office
Gloria Traina, Adviser, Norwegian Ministry of Health and Care Services
13:45 Health Data Panel
Arto Vuori, Head of Data and Analytics Unit, Finnish Institute for Health and Welfare (THL)
Sofie Björling, Head of the Department of Research Infrastructures at the Swedish Research Council
Marianne Braaten, Programme owner, Health Analysis Platform, Norwegian
Directorate of E-Health
Stina Salomonsson, Executive Director, Outcomes Research - CORE Regional Team lead, MSD
Pål Hasvold, PhD, Medical Evidence Director, Astra Zeneca
14:15 Break
14:30 Clinical Trials Panel
Marianne van der Wel, Senior advisor, Ministry of Health and Care Services (Norway)
Gunilla Andrew Nielsen, Head of Clinical trials, Medical Products Agency (Sweden)
Marianne Pilgaard, CEO, Trial Nation (Denmark)
Judith Love, Country President and Oncology General Manager Nordics, Novartis
Lars Franksson, Medical Director, Roche
15:00 Final reflection Nordic Pharma Association Panel
Ida Sofie Jensen, CEO, Danish Association of the Pharmaceutical Industry (Lif)
Anders Blanck, CEO, Lif – the research-based pharmaceutical industry (Sweden)
Nadia Tamminen, Senior advisor, Pharma Industry Finland (Pif)
Monica Larsen, Senior advisor, Business and innovation policy, Association of the Pharmaceutical Industry in Norway (LMI)
15:25 Closing remarks
Anders Blanck, CEO, Lif – the research-based pharmaceutical industry (Sweden)